Bharat Immunologicals & Biologicals (BOM:524663) LT-Debt-to-Total-Asset : 0.02 (As of Sep. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Bharat Immunologicals & Biologicals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Bharat Immunologicals & Biologicals's long-term debt to total assests ratio for the quarter that ended in Sep. 2023 was 0.02.

Bharat Immunologicals & Biologicals's long-term debt to total assets ratio increased from Sep. 2022 (0.00) to Sep. 2023 (0.02). It may suggest that Bharat Immunologicals & Biologicals is progressively becoming more dependent on debt to grow their business.

Bharat Immunologicals & Biologicals LT-Debt-to-Total-Asset Historical Data

The historical data trend for Bharat Immunologicals & Biologicals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bharat Immunologicals & Biologicals LT-Debt-to-Total-Asset Chart

Bharat Immunologicals & Biologicals Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

Bharat Immunologicals & Biologicals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	0.02

Bharat Immunologicals & Biologicals LT-Debt-to-Total-Asset Calculation

Bharat Immunologicals & Biologicals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2023 is calculated as

LT Debt to Total Assets (A: Mar. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2023 )	/	Total Assets (A: Mar. 2023 )
	=	0	/	1886.473
	=	0.00

Bharat Immunologicals & Biologicals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

LT Debt to Total Assets (Q: Sep. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2023 )	/	Total Assets (Q: Sep. 2023 )
	=	35	/	1881.313
	=

Bharat Immunologicals & Biologicals (BOM:524663) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Bharat Immunologicals & Biologicals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Bharat Immunologicals & Biologicals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Bharat Immunologicals & Biologicals (BOM:524663) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bharat Immunologicals & Biologicals Corp Ltd (BOM:524663) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Village Chola, BIBCOL, OPV Plant, Bulandshahar, UP, IND, 203203

Website

http://www.bibcol.sciencecentral.in

Bharat Immunologicals & Biologicals Corp Ltd is an India-based biotechnology company. It primarily manufactures Oral polio vaccines. In addition, the company also manufactures zinc tablets, diarrhea management kits, and Ready to Use Therapeutic Food (RUTF). It also manufactures nutraceuticals and biological products for the treatment of health deficiencies and disorders. The firm is organized into three segments: Oral Polio Vaccine, Zinc Tablets, and BIB VIT, BIBSANIT. The group principally operates in India and generates the majority of its revenue from sales of Oral polio vaccines.

Bharat Immunologicals & Biologicals (BOM:524663) Headlines

No Headlines